Chemistry: natural resins or derivatives; peptides or proteins; – Peptides of 3 to 100 amino acid residues – 11 to 14 amino acid residues in defined sequence
Reexamination Certificate
2007-11-13
2007-11-13
Shukla, Ram R. (Department: 1631)
Chemistry: natural resins or derivatives; peptides or proteins;
Peptides of 3 to 100 amino acid residues
11 to 14 amino acid residues in defined sequence
Reexamination Certificate
active
09845715
ABSTRACT:
The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with reference to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of at least one disease state relative to recognition of the presence and/or the absence of the biopolymer.
REFERENCES:
patent: 5062935 (1991-11-01), Schlag et al.
patent: 5538897 (1996-07-01), Yates, III et al.
patent: 5849297 (1998-12-01), Harrison et al.
patent: 6020208 (2000-02-01), Hutchens et al.
patent: WO 87/06344 (1987-10-01), None
patent: WO 90/14148 (1990-11-01), None
patent: WO 91/13352 (1991-09-01), None
patent: WO 93/24834 (1993-12-01), None
patent: WO 98/07036 (1998-02-01), None
patent: WO 98/23290 (1998-07-01), None
patent: WO 00/49410 (2000-08-01), None
Tang, et al., “Contribution of Renal Secreted Completed C3 to the Circulating Pool in Humans1”, Journal of Immunology (1999), vol. 162, No. 7, pp. 4336-4341.
Koch, et al., “A Novel Polymorphism of Human Complement Component C3 Detected by Means of a Monoclonal Antibody”, Immunogenetics (1986), vol. 23, No. 5, pp. 322-325.
Beaudry, et al., “Complement C3 (C3F) As a Risk Factor for Stroke”, Stroke (1990), vol. 21, No. 1, p. 168.
Muscari, et al., “Association of Serum C3 Levels With the Risk of Myocardial Infarction”, American Journal of Medicine (1995), vol. 98, No. 4, pp. 357-364.
Harrison et al., “Structure of C3f, a Small Peptide Specifically Released during Inactivation of the Third Component of Complement”, Component (1988), vol. 5, No. 1, pp. 27-32.
Agarwal, et al., “Immunologic Parameters in Infective Endocarditis: A Prospective Study”, Indian Heart Journal (May 1991), vol. 43, No. 3, pp. 179-183.
Kristensen, et al., “Association Between Coronary Heart Disease and the C3F—Gene in Essential Hypertension”, Circulation (1978), vol. 58, No. 4, pp. 622-625.
Richter et al, Composition of the peptide fraction in human blood plasma: database of circulating human peptides, J. Chrom. B. Biomed. Sci. Appl., 726, 1-2, (1999), pp. 25-35.
Takahashi et al, Rapid and sensitive immunoassay for the measurement of serum S100B using isoform-specific monoclonal antibody, Clin. Chem., 45, 8, (1999), pp. 1307-1311.
Jackowski George
Marshall John
Thatcher Brad
Vrees Tammy
Yantha Jason
McHale & Slavin P.A.
Nanogen Inc.
Shukla Ram R.
Skibinsky Anna
LandOfFree
Biopolymer marker indicative of disease state having a... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Biopolymer marker indicative of disease state having a..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Biopolymer marker indicative of disease state having a... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3810902